Selected article for: "aplastic anemia and hmpv infection"
Author: Chu, Helen Y.; Renaud, Christian; Ficken, Elle; Thomson, Blythe; Kuypers, Jane; Englund, Janet A.
Title: Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children
  • Document date: 2014_10_21
    • ID: ujvbm6ae_8
    Snippet: Overall, 55 hMPV-infected immunocompromised patients were identified from May 29, 2006 to March 26, 2010. The characteristics of these patients are listed in Table 1 . The median age was 5 years (range, 5 months-19 years), and the majority had a hematologic malignancy as an underlying condition. Of these, most had acute lymphoblastic leukemia (ALL) (n = 21; 88%). The nine solid tumors included Wilms tumor (n = 3; 33%), osteosarcoma (n = 1; 11%), .....
    Document: Overall, 55 hMPV-infected immunocompromised patients were identified from May 29, 2006 to March 26, 2010. The characteristics of these patients are listed in Table 1 . The median age was 5 years (range, 5 months-19 years), and the majority had a hematologic malignancy as an underlying condition. Of these, most had acute lymphoblastic leukemia (ALL) (n = 21; 88%). The nine solid tumors included Wilms tumor (n = 3; 33%), osteosarcoma (n = 1; 11%), and ovarian cancer (n = 1; 11%). Nine (16%) patients were undergoing HSCT. Indications for transplant included aplastic anemia (n = 4; 44%) and severe combined immunodeficiency (SCID) (n = 2; 22%). Eight (15%) patients were solid organ transplant recipients, and all were receiving immunosuppressive therapy. Eight (15%) hMPV infections were acquired nosocomially, while 46 (85%) were community acquired. Of these 46 cases, 24 (52%) patients were hospitalized for evaluation of their hMPV infection.

    Search related documents:
    Co phrase search for related documents
    • acute lymphoblastic leukemia and hmpv infection: 1
    • acute lymphoblastic leukemia and HSCT undergo: 1
    • acute lymphoblastic leukemia and immunocompromised patient: 1, 2, 3
    • acute lymphoblastic leukemia and immunosuppressive therapy: 1, 2
    • acute lymphoblastic leukemia and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lymphoblastic leukemia and median age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • community acquire and immunosuppressive therapy: 1
    • community acquire and median age: 1
    • hematologic malignancy and hmpv infection: 1, 2, 3
    • hematologic malignancy and immunocompromised patient: 1
    • hematologic malignancy and immunosuppressive therapy: 1, 2, 3
    • hematologic malignancy and lymphoblastic leukemia: 1
    • hematologic malignancy and median age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • hmpv infection and immunosuppressive therapy: 1
    • hmpv infection and lymphoblastic leukemia: 1
    • hmpv infection and median age: 1, 2, 3, 4, 5
    • HSCT undergo and lymphoblastic leukemia: 1
    • immunocompromised patient and lymphoblastic leukemia: 1, 2, 3
    • immunocompromised patient and median age: 1, 2, 3, 4